Trials / Terminated
TerminatedNCT02916056
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 297 (actual)
- Sponsor
- vTv Therapeutics · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azeliragon 5mg |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-06-01
- Completion
- 2018-06-01
- First posted
- 2016-09-27
- Last updated
- 2021-06-01
- Results posted
- 2021-06-01
Locations
71 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02916056. Inclusion in this directory is not an endorsement.